Cyclacel Pharmaceuticals, Inc. (CYCC)
CYCC moved a median of -0.21% 30 minutes after news, and -1.80% by the close. How CYCC actually reacts to news — the realized, point-in-time move the market made, measured across 238 labeled events over the last three years with zero look-ahead.
CYCC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.24% | 34% | 221 |
| 30-min | -0.21% | 42% | 229 |
| 60-min | -0.36% | 45% | 229 |
| to close | -1.80% | 38% | 228 |
| Middle 50% of CYCC reactions | -3.34% to +1.47% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 238 |
Half of all Cyclacel Pharmaceuticals, Inc. news events land between -3.34% and +1.47% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CYCC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CYCC's baseline. Nothing else.
Recent CYCC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K/A Bio Green Med Solution, For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Bio Green Med Solution, For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | Press release | GlobeNewswire | — | — | |
| Form 8-K Cyclacel Pharmaceuticals For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form EFFECT Cyclacel Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Cyclacel Pharmaceuticals For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +1.74% | +3.49% | |
| Form 8-K Cyclacel Pharmaceuticals For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.52% | |
| Form 8-K Cyclacel Pharmaceuticals For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | -5.18% | |
| Form POS AM Cyclacel Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | -0.49% | -5.18% | |
| Form 8-K Cyclacel Pharmaceuticals For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | -2.60% | -2.98% | |
| Form DEFA14A Cyclacel Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.53% | |
| Form POS AM Cyclacel Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | +0.75% | -0.13% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.77% | +1.95% | |
| Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.77% | +1.95% | |
| Form 8-K Cyclacel Pharmaceuticals For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | -1.22% | |
| Form 8-K Cyclacel Pharmaceuticals For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +1.95% | |
| Form EFFECT Cyclacel Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -5.48% | -22.40% | |
| CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB | Press release | GlobeNewswire | -5.48% | -22.40% | |
| Form S-1/A Cyclacel Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | -3.21% | -7.66% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | — | |
| Form EFFECT Cyclacel Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.03% | -2.22% | |
| Form POS AM Cyclacel Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | +1.41% | -7.20% | |
| Form S-1 Cyclacel Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | +1.41% | -7.20% | |
| Form S-4 Cyclacel Pharmaceuticals | SEC filing · Form S-4 | SEC EDGAR | +1.41% | -7.20% | |
| Form S-8 POS Cyclacel Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +1.41% | -7.20% | |
| CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY | Press release | GlobeNewswire | -2.67% | -12.02% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -2.67% | -12.02% | |
| CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT | Press release | GlobeNewswire | -13.01% | -8.93% | |
| CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER | Press release | GlobeNewswire | -13.01% | -8.93% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -13.01% | -8.93% | |
| Form DEF 14C Cyclacel Pharmaceuticals For: Jul 07 | SEC filing · Form DEF | SEC EDGAR | -0.92% | +1.21% | |
| Cyclacel Pharmaceuticals Announces Stock Split | Press release | GlobeNewswire | -17.88% | -14.52% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -17.88% | -14.52% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -3.08% | +0.39% | |
| Form DEFA14A Cyclacel Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +2.39% | -1.47% | |
| Form PRE 14C Cyclacel Pharmaceuticals For: Jun 25 | SEC filing · Form PRE | SEC EDGAR | +0.73% | +2.27% | |
| Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock | Press release | GlobeNewswire | +1.36% | -0.85% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +1.36% | -0.85% | |
| CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT | Press release | GlobeNewswire | -1.24% | -10.49% | |
| Form 8-K Cyclacel Pharmaceuticals For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -10.49% | |
| Form DEF 14C Cyclacel Pharmaceuticals For: May 23 | SEC filing · Form DEF | SEC EDGAR | +1.39% | +12.50% | |
| CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE | Press release | GlobeNewswire | +1.00% | -5.58% | |
| Form 8-K Cyclacel Pharmaceuticals For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -4.76% | |
| Form 10-Q Cyclacel Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.00% | -5.58% | |
| Form PRE 14C Cyclacel Pharmaceuticals For: May 13 | SEC filing · Form PRE | SEC EDGAR | -10.11% | -16.25% | |
| CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | Press release | GlobeNewswire | +0.00% | +9.69% | |
| Form 8-K Cyclacel Pharmaceuticals For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -6.44% | |
| CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE | Press release | GlobeNewswire | -0.24% | +16.07% | |
| Form 8-K Cyclacel Pharmaceuticals For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.69% | |
| Form EFFECT Cyclacel Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -2.78% | +3.99% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CYCC section they belong to.
Where else CYCC is measured.
CYCC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
| Ovid Therapeutics Inc. (OVID) | 239 | -0.32% | 40% |
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
| Retractable Technologies, Inc. (RVP) | 237 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cyclacel Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CYCC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 238 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of CYCC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CYCC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.